Hims & Hers Partners with Novo Nordisk
What happened
Hims & Hers finalized a deal with Novo Nordisk to sell GLP-1 weight-loss drugs via its platform, overcoming previous legal disputes. This signals the rising power of telehealth as a distribution channel for medication and digital coaching, reinforcing the need for clinical integration and trust.
Why it matters
The partnership allows Hims & Hers to offer medications like Wegovy and Ozempic, pending online consultations. Novo Nordisk had previously taken legal action against telehealth platforms selling compounded versions of its drugs. The agreement comes as demand for GLP-1 receptor agonists surges, driven by their effectiveness in weight management and treatment of type 2 diabetes. Some analysts predict the GLP-1 market could reach $100 billion by 2030. Hims & Hers shares jumped as much as 25% following reports of the deal, reflecting investor confidence in the collaboration. The company aims to provide access to these medications with personalized support and guidance, addressing concerns about appropriate usage. This move positions Hims & Hers as a significant player in the evolving landscape of telehealth and prescription weight loss solutions. Competitors like Ro and Found also offer weight management programs, creating a competitive market for telehealth providers.
Key numbers
- Hims & Hers finalized a deal with Novo Nordisk to sell GLP-1 weight-loss drugs via its platform, overcoming previous legal disputes.
- The agreement comes as demand for GLP-1 receptor agonists surges, driven by their effectiveness in weight management and treatment of type 2 diabetes.
- Some analysts predict the GLP-1 market could reach $100 billion by 2030.
- Hims & Hers shares jumped as much as 25% following reports of the deal, reflecting investor confidence in the collaboration.
What happens next
- Some analysts predict the GLP-1 market could reach $100 billion by 2030.
- The company aims to provide access to these medications with personalized support and guidance, addressing concerns about appropriate usage.
Sources
Quick answers
What happened in Hims & Hers Partners with Novo Nordisk?
Hims & Hers finalized a deal with Novo Nordisk to sell GLP-1 weight-loss drugs via its platform, overcoming previous legal disputes. This signals the rising power of telehealth as a distribution channel for medication and digital coaching, reinforcing the need for clinical integration and trust.
Why does Hims & Hers Partners with Novo Nordisk matter?
The partnership allows Hims & Hers to offer medications like Wegovy and Ozempic, pending online consultations. Novo Nordisk had previously taken legal action against telehealth platforms selling compounded versions of its drugs. The agreement comes as demand for GLP-1 receptor agonists surges, driven by their effectiveness in weight management and treatment of type 2 diabetes. Some analysts predict the GLP-1 market could reach $100 billion by 2030. Hims & Hers shares jumped as much as 25% following reports of the deal, reflecting investor confidence in the collaboration. The company aims to provide access to these medications with personalized support and guidance, addressing concerns about appropriate usage. This move positions Hims & Hers as a significant player in the evolving landscape of telehealth and prescription weight loss solutions. Competitors like Ro and Found also offer weight management programs, creating a competitive market for telehealth providers.
